Date:_2022/9/1
Your Name: Lijun Lou
Manuscript Title: Prolonged cannulation time and the uses of advanced cannulation techniques are independent risk
factors for moderate-to-severe post-ERCP pancreatitis: a large cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None National Natural Science Foundation of China	This research was supported by a grant from the National Natural Science Foundation of China (81970557).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
_	educational events				
6	Payment for expert	XNone			
	testimony				
7	Comment for attending	V. Nov.			
7	Support for attending meetings and/or travel	_ XNone			
	,				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	_ XNone			
	otos. or otook options				
12	Receipt of equipment,	_ XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dlas	Discontinuous the short conflict of interest in the following how				

The author receives support from the National Natural Science Foundation of China (81970557).	

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/9/1			
	r Name: Xu Wang			
			of advanced cannulation techniques are independent ris	sk
	ors for moderate-to-severe			_
	nuscript number (if known):	•		
rela part to ti	ted to the content of your mailes whose interests may be ransparency and does not no	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias.	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a	
reia	tionship/activity/interest, it	is preferable that you do s		
	following questions apply to	o the author's relationships	s/activities/interests as they relate to the <u>current</u>	
	·		<u>efined broadly</u> . For example, if your manuscript pertains	S
med In it	lication, even if that medica em #1 below, report all sup	tion is not mentioned in th	Il relationships with manufacturers of antihypertensive e manuscript. in this manuscript without time limit. For all other	
med In it	lication, even if that medica em #1 below, report all sup ns,	tion is not mentioned in the port for the work reported the past 36 months.	e manuscript. in this manuscript without time limit. For all other Specifications/Comments	
med In it	lication, even if that medica em #1 below, report all sup ns,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your	
nec n it ten	lication, even if that medica em #1 below, report all sup ns,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate	e manuscript. in this manuscript without time limit. For all other Specifications/Comments	
nec n it ten	lication, even if that medica em #1 below, report all sup ns,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your	
nec n it ten	lication, even if that medica em #1 below, report all sup ns,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)	
n it tem the	lication, even if that medica em #1 below, report all suppless, time frame for disclosure is	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)	
in it item	lication, even if that medical em #1 below, report all supposs, time frame for disclosure is	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	
med In it	lication, even if that medical em #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the	
in it item	All support for the present manuscript (e.g., funding, provision of study materials,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the National Natural Science Foundation of China	
in it item	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the	
in it item	All support for the present manuscript (e.g., funding, provision of study materials,	tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	e manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the National Natural Science Foundation of China	

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

The author receives support from the National Natural Science Foundation of China (819)	70557).

	ICMJE DISCLOSURE FORM			
Dat	te:2022/9/1			
	ur Name:_Yan Zhang			
Ma	nuscript <u>Title:Prolonged cannu</u>	lation time and the uses	of advanced cannulation techniques are independent risk	
fact	tors for moderate-to-severe po	ost-ERCP pancreatitis: a la	rge cohort study	
Ma	nuscript number (if known):			
rela par to t	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.			
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
iter		·	in this manuscript without time limit. For all other	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None National Natural Science Foundation of China	This research was supported by a grant from the National Natural Science Foundation of China (81970557).
		Time frame: past	36 months

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

The author receives support from the National Natural Science Foundation of China (819)	70557).

	ICMJE DISCLOSURE FORM			
Dat	e:2022/9/1			
	r Name:Hui Luo			
Maı	nuscript <u>Title:Prolonged can</u>	nulation time and the uses	of advanced cannulation techniques are independent risk	
<u>fact</u>	ors for moderate-to-severe	post-ERCP pancreatitis: a la	rge cohort study	
Maı	nuscript number (if known):			
rela part to t	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
	following questions apply to nuscript only.	o the author's relationships	s/activities/interests as they relate to the current	
to t	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
iten			in this manuscript without time limit. For all other	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	

Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. This research was supported by a grant from the National Natural Science Foundation of China (81970557).			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) National Natural Science This research was supported by a grant from the National Natural Science Foundation of China (81970557).			Time frame: Since the initial	planning of the work
	m p m	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	National Natural Science	National Natural Science Foundation of China

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

The author receives support from the National Natural Science Foundation of China (819)	70557).

ICMJE DISCLOSURE FORM
Date:2022/9/1
Your Name:_Gui Ren
Manuscript Title:Prolonged cannulation time and the uses of advanced cannulation techniques are independent risk
factors for moderate-to-severe post-ERCP pancreatitis: a large cohort study
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None National Natural Science Foundation of China Time frame: past	This research was supported by a grant from the National Natural Science Foundation of China (81970557).

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

The author receive	es support from the Nati	onal Natural Science F	oundation of China (819	970557).

Date	e:2022/9/1						
You	Your Name:_Linhui Zhang						
Mar	uscript <u>Title:Prolonged can</u>	nulation time and the uses	of advanced cannulation techniques are independent risk				
fact	ors for moderate-to-severe	post-ERCP pancreatitis: a l	arge cohort study_				
Mar	uscript number (if known):						
In th	e interest of transparency,	we ask you to disclose all ı	relationships/activities/interests listed below that are				
	·	•	ns any relation with for-profit or not-for-profit third				
-	•	· ·	the manuscript. Disclosure represents a commitment				
	•	-	If you are in doubt about whether to list a				
rela	tionship/activity/interest, it	is preferable that you do	so.				
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>				
item		•	in this manuscript without time limit. For all other				
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate	institution)				
		none (add rows as					
		needed)					
		Time frame: Since the initia	l planning of the work				
1	All support for the present	None					
	manuscript (e.g., funding,	National Natural Science	This research was supported by a grant from the				
	provision of study materials,	Foundation of China	National Natural Science Foundation of China				
	medical writing, article		(81970557).				
	processing charges, etc.)						
	No time limit for this item.						

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

The author receive	es support from the Nati	onal Natural Science F	oundation of China (819	970557).

Date	e:2022/9/1					
our Name:_Shuihui Liang						
Mar	nuscript <u>Title:Prolonged can</u> ı	nulation time and the uses	of advanced cannulation techniques are independent ris	<u>sk</u>		
fact	ors for moderate-to-severe	post-ERCP pancreatitis: a la	arge cohort study			
Mar	nuscript number (if known):					
rela part to ti	ted to the content of your m ties whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
	following questions apply to	o the author's relationship	s/activities/interests as they relate to the <u>current</u>			
Γhe	author's relationships/activ	ities/interests should be d	efined broadly. For example, if your manuscript pertains	,		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all sup	nsion, you should declare a tion is not mentioned in the port for the work reported	in this manuscript without time limit. For all other	;		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments	:		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your	;		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments	•		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your	;		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)	;		
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)	:		
n it tem	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)			
n it tem	he epidemiology of hyperter dication, even if that medical tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the			
n it tem	he epidemiology of hyperter dication, even if that medicatem #1 below, report all supports, time frame for disclosure is	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone	Ill relationships with manufacturers of antihypertensive te manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work			
n it	he epidemiology of hyperter dication, even if that medical tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	Ill relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the	•		
n it tem	he epidemiology of hyperter dication, even if that medicatem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	Ill relationships with manufacturers of antihypertensive te manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the National Natural Science Foundation of China			
n it tem	he epidemiology of hyperter dication, even if that medical tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialNone National Natural Science	Ill relationships with manufacturers of antihypertensive te manuscript. in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work This research was supported by a grant from the National Natural Science Foundation of China			

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_		., .,	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
14	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_	
	financial interests		

The author receives support from the National Natural Science Foundation of China (819)	70557).

te:2022/9/1	
ur Name:Xiaoyu Kang	
unuscript <u>Title:Prolonged cannulation time and the uses of advanced cannulation techniques are independented</u>	t risk
tors for moderate-to-severe post-ERCP pancreatitis: a large cohort study	
nuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None National Natural Science Foundation of China	This research was supported by a grant from the National Natural Science Foundation of China (81970557).

		Time frame: past 36 months
2	Grants or contracts from	XNone
	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
12	Services Other financial or non	V. None
13	Other financial or non- financial interests	XNone
	ilianciai iliterests	

e author re	eceives support from	n the National Nat	ural Science Founda	tion of China (81970557).	

	e:2022/9/1 rr Name:Xin Shi		
			s of advanced cannulation techniques are independent ris
	ors for moderate-to-severe		
	nuscript number (if known):		
rela part to t rela	ted to the content of your matter whose interests may be ransparency and does not not itionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	nuscript only.		
The	author's relationships/activ	ities/interests should be <u>c</u>	lefined broadly. For example, if your manuscript pertains
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all sup	nsion, you should declare a tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported	all relationships with manufacturers of antihypertensive he manuscript.
o t nec n it ten	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare ation is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this	all relationships with manufacturers of antihypertensive he manuscript. If in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare ation is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	all relationships with manufacturers of antihypertensive he manuscript. If in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your
n it	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)
n it ten	he epidemiology of hyperter dication, even if that medica em #1 below, report all supp ns, time frame for disclosure is	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)
n it	he epidemiology of hyperter dication, even if that medicatem #1 below, report all supports, time frame for disclosure is	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaNone	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)
n it ten	he epidemiology of hyperter dication, even if that medical tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaNone National Natural Science	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work This research was supported by a grant from the
n it ten	he epidemiology of hyperter dication, even if that medicate tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaNone	All relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work This research was supported by a grant from the National Natural Science Foundation of China
n it ten	he epidemiology of hyperter dication, even if that medical tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaNone National Natural Science	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work This research was supported by a grant from the
n it nec	he epidemiology of hyperter dication, even if that medicate tem #1 below, report all supports, time frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials,	nsion, you should declare a tion is not mentioned in the port for the work reported the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaNone National Natural Science	All relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work This research was supported by a grant from the National Natural Science Foundation of China

Time frame: past 36 months

2
2
2
2
2

The author receives support from the National Natural Science Foundation of China (819)	70557).

Date:2022/9/1	
Your Name:Long Chen	
Manuscript <u>Title:Prolonged cannulation time and the uses of advanced cannulation techniques are in</u>	ndependent risk
factors for moderate-to-severe post-ERCP pancreatitis: a large cohort study	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	National Natural Science	This research was supported by a grant from the
	provision of study materials,	Foundation of China	National Natural Science Foundation of China
	medical writing, article		(81970557).
	processing charges, etc.)		
	No time limit for this item.		

		Time frame: past 36 months
2	Grants or contracts from	_XNone
	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending meetings and/or travel	XNone
	meetings and/or traver	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	XNone
	financial interests	

he author re	ceives support from th	e National Natura	l Science Foundation	of China (81970557).	

	ICMJE DISCLOSURE FORM			
Date	e:2022/9/1			
You	r Name:_Yong Lv			
Mar	nuscript <u>Title:Prolonged can</u>	nulation time and the uses	of advanced cannulation techniques are independent risk	
fact	ors for moderate-to-severe	post-ERCP pancreatitis: a la	arge cohort study	
Mar	nuscript number (if known):		-	
rela part to ti	ted to the content of your n	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias.	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following questions apply touscript only.	o the author's relationships	s/activities/interests as they relate to the <u>current</u>	
to tl	• •	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
iten	•		in this manuscript without time limit. For all other	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	National Natural Science	This research was supported by a grant from the
	provision of study materials,	Foundation of China	National Natural Science Foundation of China
	medical writing, article		(81970557).
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months

2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Receipt of equipment,	V None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author receive	es support from the Nati	onal Natural Science F	oundation of China (819	970557).

Date:2022	2/9/1
Your Name:	Xiangping Wang
Manuscript	
factors for m	noderate-to-severe post-ERCP pancreatitis: a large cohort study
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	National Natural Science	This research was supported by a grant from the
	provision of study materials,	Foundation of China	National Natural Science Foundation of China
	medical writing, article		(81970557).
	processing charges, etc.)		
	No time limit for this item.		

		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	V None	
13	financial interests	XNone	
	inianciai interests		

ne author rec	eives support from the	National Natural	Science Foundation	of China (81970557).	

Date:2022/9/1	
Your Name:Yanglin Pan	
Manuscript Title:Prolonged cannulation time and the uses of advanced cannulation technology	 niques are independent risk
factors for moderate-to-severe post-ERCP pancreatitis: a large cohort study	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	National Natural Science	This research was supported by a grant from the
	provision of study materials,	Foundation of China	National Natural Science Foundation of China
	medical writing, article		(81970557).
	processing charges, etc.)		
	No time limit for this item.		

		Time frame: past 36 months
2	Grants or contracts from	XNone
	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
12	Services Other financial or non	V. None
13	Other financial or non- financial interests	XNone
	ilianciai iliterests	

The aut	thor receives support fr	om the National Na	tural Science Found	ation of China (81970	9557).

Please summarize the above conflict of interest in the following box: